Kiniksa Pharmaceuticals develops and sells ARCALYST, a treatment for recurrent pericarditis and other inflammatory conditions. It last closed at $95.11 on Nov 17, up 0.93% on the day. The average 12-month price target from 5 analysts is $110.00 (+15.7% from the last close), with a high of $122.00 and a low of $101.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $1000K, the largest $1000K.
Each firm's latest rating on KNSA in the past 90 days
Average 12-month target
$110.00
▲ 15.7% upside
Based on 5 analysts who set a price target on KNSA in the past 90 days. The average target is $110.00, with a high of $122.00 and a low of $101.00, compared with the last close of $95.11.
Low $101.00Avg $110.00High $122.00
Blue marker: last close $95.11
Highest target$122.00
Average target$110.00
Lowest target$101.00
Latest rating changes
TD CowenMaintained
Nov 17Buy$115
JP MorganTarget raised
Oct 30Buy$107 → $122
Goldman SachsTarget raised
Oct 28Buy$90 → $101
WedbushTarget raised
Oct 28Buy$99 → $102
Wells FargoMaintained
Oct 28Buy$110
Date
Firm
Action
Rating
Price target
Nov 17
TD Cowen
Maintained
Buy
$115
Oct 30
JP Morgan
Target raised
Buy
$107 → $122
Oct 28
Goldman Sachs
Target raised
Buy
$90 → $101
Oct 28
Wedbush
Target raised
Buy
$99 → $102
Oct 28
Wells Fargo
Maintained
Buy
$110
Loading…
Technical Analysis
KNSA · as of the Nov 17 close · updated after every close
Uptrend
The stock is 4% above its 20 day and 13% above its 50 day average. It is 33% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 58). The nearest support is the Pivot at $94.57, and the nearest resistance the Pivot R1 at $95.79.
Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.5%/day
Key levels
$99.3152 week high+4.4%
$98.48Swing high (Oct 30)+3.5%
$95.79Pivot R1+0.7%
$95.11Last close
$94.57Pivot−0.6%
$93.90Pivot S1−1.3%
$90.9120 day average−4.4%
$87.30Swing low (Nov 5)−8.2%
$82.8650 day average−12.9%
$77.55100 day average−18.5%
$63.33200 day average−33.4%
$37.0252 week low−61.1%
Indicators
RSI (14)
57.96
Middle of its range
Neutral
MACD
4.03
Below its signal line
Bearish
Stochastic
68.4
Middle of its range
Neutral
ADX (14)
19.1
No clear trend
Williams %R
-35.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
46.4
Oversold below −100, overbought above 100
Neutral
Rate of change
+1.9%
Change over 10 sessions
Bullish
ATR (14)
$4.30
Typical daily range, 4.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Rising, overbought
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchOverbought
VolatilityNormal, 7.4%/day
Key levels
$99.3152 week high+4.4%
$98.48Swing high (Oct 30)+3.5%
$95.79Pivot R1+0.7%
$95.11Last close
$94.57Pivot−0.6%
$93.90Pivot S1−1.3%
$90.9120 day average−4.4%
$87.30Swing low (Nov 5)−8.2%
$82.8650 day average−12.9%
$77.55100 day average−18.5%
$63.33200 day average−33.4%
$37.0252 week low−61.1%
Indicators
RSI (14)
77.39
Overbought above 70
Overbought
MACD
9.50
Above its signal line
Bullish
Stochastic
86.1
Near the top of its range
Overbought
ADX (14)
50.5
Strong uptrend
Williams %R
-14.7
Oversold below −80, overbought above −20
Overbought
CCI (20)
185.0
Oversold below −100, overbought above 100
Overbought
Rate of change
+24.7%
Change over 10 sessions
Bullish
ATR (14)
$7.03
Typical daily range, 7.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200–
What happened before, for KNSA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how KNSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow KNSA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How KNSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KNSA is in one of them and how their past KNSA trades turned out.
Kiniksa Pharmaceuticals is a drug developer based in London that focuses on cardiovascular diseases. Its main product, ARCALYST, is approved in the United States for recurrent pericarditis, an inflammatory condition of the heart lining, and for certain autoinflammatory syndromes. The company sells ARCALYST in the United States through specialty pharmacies, has licensed partners in other regions, and is developing KPL-387, an investigational antibody that targets the same inflammation pathway. Its customers are patients and the doctors who treat them.